CMVLF (Cellectis) Cyclically Adjusted Revenue per Share: $0.65 (As of Mar. 2026)


CMVLF Cellectis SA CMVLF
60 GF Score
Price $3.47
GF Value $3.99
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Cyclically Adjusted Revenue per Share?

Cellectis CMVLF 60 Cyclically Adjusted Revenue per Share is $0.65 as of Mar. 2026. GuruFocus rates CMVLF with a GF Score™ of 60/100 and a GF Value™ of $3.99 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cellectis's adjusted revenue per share for the three months ended in Mar. 2026 was $0.057. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.65 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cellectis's average Cyclically Adjusted Revenue Growth Rate was -14.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cellectis was -4.60% per year. The lowest was -8.50% per year. And the median was -6.55% per year.

As of today (2026-07-09), Cellectis's current stock price is $3.47. Cellectis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.65. Cellectis's Cyclically Adjusted PS Ratio of today is 5.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cellectis was 12.13. The lowest was 1.18. And the median was 3.26.


Cellectis  (OTCPK:CMVLF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cellectis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.47/0.65
=5.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cellectis was 12.13. The lowest was 1.18. And the median was 3.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cellectis Cyclically Adjusted Revenue per Share Related Terms


Cellectis Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cellectis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Cyclically Adjusted Revenue per Share Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.85 0.81 0.66 0.65

Cellectis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.68 0.77 0.65 0.65

CMVLF vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PS Ratio falls into.


CMVLF
60GF Score
Cellectis SA CMVLF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectis's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.057/122.4300*122.4300
=0.057

Current CPI (Mar. 2026) = 122.4300.

Cellectis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.496 100.630 0.603
201609 0.315 100.340 0.384
201612 0.230 100.650 0.280
201703 0.188 101.170 0.228
201706 0.183 101.320 0.221
201709 0.170 101.330 0.205
201712 0.161 101.850 0.194
201803 0.168 102.750 0.200
201806 0.120 103.370 0.142
201809 0.021 103.560 0.025
201812 0.020 103.470 0.024
201903 0.024 103.890 0.028
201906 0.027 104.580 0.032
201909 0.200 104.500 0.234
201912 0.104 104.980 0.121
202003 1.180 104.590 1.381
202006 0.068 104.790 0.079
202009 0.145 104.550 0.170
202012 -0.211 104.960 -0.246
202103 0.597 105.750 0.691
202106 0.246 106.340 0.283
202109 0.183 106.810 0.210
202112 -0.324 107.850 -0.368
202203 0.037 110.490 0.041
202206 0.029 112.550 0.032
202209 0.004 112.740 0.004
202212 0.351 114.160 0.376
202303 0.003 116.790 0.003
202306 0.003 117.650 0.003
202309 0.003 118.260 0.003
202312 0.004 118.390 0.004
202403 0.044 119.470 0.045
202406 0.090 120.200 0.092
202409 0.162 119.560 0.166
202412 0.127 119.950 0.130
202503 0.106 120.380 0.108
202506 0.167 121.360 0.168
202509 0.346 120.950 0.350
202512 0.104 120.900 0.105
202603 0.057 122.430 0.057

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.65 mean?
Cellectis (CMVLF) has a Cyclically Adjusted Revenue per Share of $0.65 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cellectis and its competitors.
Is Cellectis' Cyclically Adjusted Revenue per Share too high?
Cellectis' current Cyclically Adjusted Revenue per Share is $0.65. Overall, Cellectis has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Cellectis' Cyclically Adjusted Revenue per Share of $0.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cellectis and its competitors. Cellectis's current Cyclically Adjusted Revenue per Share is $0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.99, compared to a current price of $3.47 — trading 13% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.65. Cellectis' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cellectis (CMVLF), the current Cyclically Adjusted Revenue per Share is $0.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of $3.47 is trading 13% below its estimated GF Value™ of $3.99. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for CMVLF:

  • Cyclically Adjusted Revenue per Share: $0.65
  • GF Value™: $3.99 vs. price of $3.47 (13% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for CMVLF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.99
GF Value